Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
14.23 EUR | -1.73% | +0.43% | -10.72% |
May. 07 | Medios AG Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
May. 07 | Transcript : Medios AG, Q1 2024 Earnings Call, May 07, 2024 |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
- The company's attractive earnings multiples are brought to light by a P/E ratio at 12.17 for the current year.
- The company is one of the most undervalued, with an "enterprise value to sales" ratio at 0.25 for the 2024 fiscal year.
- The company's share price in relation to its net book value makes it look relatively cheap.
- The company has a low valuation given the cash flows generated by its activity.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- Low profitability weakens the company.
- For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-10.72% | 374M | - | ||
+37.74% | 723B | C+ | ||
+34.48% | 595B | B | ||
-2.07% | 369B | C+ | ||
+20.25% | 332B | B- | ||
+2.99% | 282B | C+ | ||
+16.94% | 244B | B+ | ||
+9.76% | 208B | B- | ||
-4.25% | 205B | A+ | ||
+2.81% | 168B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- ILM1 Stock
- Ratings Medios AG